{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:10:17Z","timestamp":1784909417039,"version":"3.55.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.tox.2019.152310","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T11:42:49Z","timestamp":1571226169000},"page":"152310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Telmisartan and captopril ameliorate pregabalin-induced heart failure in rats"],"prefix":"10.1016","volume":"428","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8073-8122","authenticated-orcid":false,"given":"Zeinab M.","family":"Awwad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4098-3078","authenticated-orcid":false,"given":"Samar O.","family":"El-Ganainy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed I.","family":"ElMallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Khattab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiman S.","family":"El-Khatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tox.2019.152310_bib0005","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1592\/phco.22.13.1173.33517","article-title":"Angiotensin II receptor blocker\u2010associated angioedema: on the heels of ACE inhibitor angioedema","volume":"22","author":"Abdi","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.tox.2019.152310_bib0010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajem.2012.02.008","article-title":"Complete atrioventricular block due to overdose of pregabalin","volume":"30","author":"Aksakal","year":"2012","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.tox.2019.152310_bib0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12012-009-9049-z","article-title":"Preventive effect of amiodarone during acute period in isoproterenol-induced myocardial injury in Wistar rats","volume":"9","author":"Albayrak","year":"2009","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.tox.2019.152310_bib0020","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/1440-1681.12360","article-title":"Comparison of the cardioprotective and renoprotective effects of the L\/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats","volume":"42","author":"Aritomi","year":"2015","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.tox.2019.152310_bib0025","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4172\/2167-1095.1000102","article-title":"Cilnidipine, an L-\/N-type calcium channel blocker, changes the circulating angiotensin-(1-7)\/angiotensin II ratio","volume":"1","author":"Aritomi","year":"2012","journal-title":"J. Hypertens Open Access."},{"key":"10.1016\/j.tox.2019.152310_bib0030","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jpain.2008.03.013","article-title":"A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia","volume":"9","author":"Arnold","year":"2008","journal-title":"J. Pain"},{"key":"10.1016\/j.tox.2019.152310_bib0035","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/hc1002.105225","article-title":"Peroxisome proliferator-activated receptor \u03b3 plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo","volume":"105","author":"Asakawa","year":"2002","journal-title":"Circulation."},{"key":"10.1016\/j.tox.2019.152310_bib0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2007.04.062","article-title":"Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis","volume":"125","author":"Bahk","year":"2008","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.tox.2019.152310_bib0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0022-2828(02)00310-3","article-title":"Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS","volume":"35","author":"Bell","year":"2003","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.tox.2019.152310_bib0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/aap.12001","article-title":"Captopril avoids hypertension, the increase in plasma angiotensin II but increases angiotensin 1-7 and angiotensin II-induced perfusion pressure in isolated kidney in SHR","volume":"32","author":"Castro-Moreno","year":"2012","journal-title":"Auton. Autacoid Pharmacol."},{"key":"10.1016\/j.tox.2019.152310_bib0055","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1161\/01.HYP.31.1.362","article-title":"Metabolism of angiotensin-(1\u20137) by angiotensin-converting enzyme","volume":"31","author":"Chappell","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.tox.2019.152310_bib0060","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1476-7120-5-34","article-title":"Role of echocardiography in diagnosis and risk stratification in heart failure with left ventricular systolic dysfunction","volume":"5","author":"Ciampi","year":"2007","journal-title":"Cardiovasc. Ultrasound"},{"key":"10.1016\/j.tox.2019.152310_bib0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11010-015-2449-4","article-title":"Intracellular angiotensin (1\u20137) increases the inward calcium current in cardiomyocytes. On the role of PKA activation","volume":"407","author":"De Mello","year":"2015","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.tox.2019.152310_bib0070","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00129784-200505060-00002","article-title":"ACE inhibitors in heart failure","volume":"5","author":"Demers","year":"2005","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.tox.2019.152310_bib0075","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.3390\/ph3072111","article-title":"Protein kinases as drug development targets for heart disease therapy","volume":"3","author":"Dhalla","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.tox.2019.152310_bib0080","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clinbiochem.2014.11.002","article-title":"Evidence based application of BNP\/NT-proBNP testing in heart failure","volume":"48","author":"Don-Wauchope","year":"2015","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.tox.2019.152310_bib0085","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fvets.2018.00136","article-title":"Pharmacokinetics of single-dose oral pregabalin administration in normal cats","volume":"5","author":"Esteban","year":"2018","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.tox.2019.152310_bib0090","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.tox.2019.152310_bib0095","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.gheart.2016.03.299","article-title":"PM097 Effects of a novel angiotensin-converting enzyme inhibitor after myocardial infarction","volume":"2","author":"Flores-Monroy","year":"2016","journal-title":"Glob. Heart"},{"key":"10.1016\/j.tox.2019.152310_bib0100","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1177\/1060028014530551","article-title":"Pregabalin-associated heart failure decompensation in a patient with a history of stage I heart failure","volume":"48","author":"Fong","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.tox.2019.152310_bib0105","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pain.2005.02.032","article-title":"Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens","volume":"115","author":"Freynhagen","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.tox.2019.152310_bib0110","doi-asserted-by":"crossref","first-page":"493129","DOI":"10.1155\/2012\/493129","article-title":"Angiotensin-(1-7)-mediated signaling in cardiomyocytes","volume":"2012","author":"Gomes","year":"2012","journal-title":"Int. J. Hypertens."},{"key":"10.1016\/j.tox.2019.152310_bib0115","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1161\/01.CIR.86.5.1566","article-title":"Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure","volume":"86","author":"Hirsch","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.tox.2019.152310_bib0120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/2046-4053-2-25","article-title":"Risk of heart failure and edema associated with the use of pregabalin: a systematic review","volume":"2","author":"Ho","year":"2013","journal-title":"Syst. Rev."},{"key":"10.1016\/j.tox.2019.152310_bib0125","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/pds.4239","article-title":"Pregabalin and heart failure: a population-based study","volume":"26","author":"Ho","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.tox.2019.152310_bib0130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.phrs.2009.05.007","article-title":"Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity","volume":"60","author":"Ibrahim","year":"2009","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.tox.2019.152310_bib0135","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1373\/clinchem.2017.275289","article-title":"Cardiovascular biomarkers in hypertensive patients with medical treatment-results from the randomized TEAMSTA protect I trial","volume":"63","author":"Jagodzinski","year":"2017","journal-title":"Clin. Chem."},{"key":"10.1016\/j.tox.2019.152310_bib0140","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/ajh\/hpt188","article-title":"Telmisartan reduces mortality and left ventricular hypertrophy with sympathoinhibition in rats with hypertension and heart failure","volume":"27","author":"Kishi","year":"2013","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.tox.2019.152310_bib0145","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1097\/HJH.0b013e32833d01dd","article-title":"A new-generation N\/L-type calcium channel blocker leads to less activation of the renin\u2013angiotensin system compared with conventional L type calcium channel blocker","volume":"28","author":"Konoshita","year":"2010","journal-title":"J. Hypertens."},{"key":"10.1016\/j.tox.2019.152310_bib0150","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/01.HYP.0000050101.90932.14","article-title":"Cardiac angiotensin II type 2 receptor activates the kinin\/NO system and inhibits fibrosis","volume":"41","author":"Kurisu","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.tox.2019.152310_bib0155","doi-asserted-by":"crossref","first-page":"H1500","DOI":"10.1152\/ajpheart.2000.278.5.H1500","article-title":"Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure","volume":"278","author":"Langenickel","year":"2000","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.tox.2019.152310_bib0160","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0254-6272(17)30016-X","article-title":"Medicinals with properties of warming Yang and tonifying Qi in terms of Traditional Chinese Medicine: their effects on left ventricular ejection fraction and aldosterone in rats with induced failure heart","volume":"36","author":"Lihua","year":"2016","journal-title":"J. Tradit. Chin. Med."},{"key":"10.1016\/j.tox.2019.152310_bib0165","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/01.CIR.0000013847.07035.B9","article-title":"Angiotensin-(1\u20137) attenuates the development of heart failure after myocardial infarction in rats","volume":"105","author":"Loot","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.tox.2019.152310_bib0170","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ejheart.2008.07.014","article-title":"State of the art: using natriuretic peptide levels in clinical practice","volume":"10","author":"Maisel","year":"2008","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.tox.2019.152310_bib0175","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1038\/s41598-018-23137-4","article-title":"Shenfu injection attenuates rat myocardial hypertrophy by up-regulating miR-19a-3p expression","volume":"8","author":"Mao","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tox.2019.152310_bib0180","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1073\/pnas.0606663104","article-title":"Protective effects of exercise and phosphoinositide 3-kinase (p110\u03b1) signaling in dilated and hypertrophic cardiomyopathy","volume":"104","author":"McMullen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tox.2019.152310_bib0185","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1161\/01.CIR.0000014763.63528.9D","article-title":"New therapeutic options in congestive heart failure: part I","volume":"105","author":"McMurray","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.tox.2019.152310_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.03.019","article-title":"Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease","volume":"164","author":"Michel","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tox.2019.152310_bib0195","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cardfail.2006.11.006","article-title":"Decompensation of chronic heart failure associated with pregabalin in patients with neuropathic pain","volume":"13","author":"Murphy","year":"2007","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.tox.2019.152310_bib0200","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10557-005-5059-7","article-title":"Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats","volume":"18","author":"Nagai","year":"2004","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.tox.2019.152310_bib0205","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1161\/CIRCULATIONAHA.115.017298","article-title":"N-terminal pro-brain natriuretic peptide and heart failure risk among individuals with and without obesity: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"133","author":"Ndumele","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.tox.2019.152310_bib0210","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1291\/hypres.30.451","article-title":"Vascular angiotensin type 1 receptor expression is associated with vascular dysfunction, oxidative stress and inflammation in fructose-fed rats","volume":"30","author":"Nyby","year":"2007","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.tox.2019.152310_bib0215","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCRESAHA.116.309128","article-title":"Advances in echocardiographic imaging in heart failure with reduced and preserved ejection fraction","volume":"119","author":"Omar","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.tox.2019.152310_bib0220","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00424-012-1146-3","article-title":"AT2 receptors: beneficial counter-regulatory role in cardiovascular and renal function","volume":"465","author":"Padia","year":"2013","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.tox.2019.152310_bib0225","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tox.2019.152310_bib0230","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/01.jcp.0000155820.74832.b0","article-title":"Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing","volume":"25","author":"Pohl","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.tox.2019.152310_bib0235","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2459\/JCM.0b013e3282fb7629","article-title":"Possible heart failure exacerbation associated with pregabalin: case discussion and literature review","volume":"9","author":"Robert Lee Page","year":"2008","journal-title":"J. Cardiovasc. Med."},{"key":"10.1016\/j.tox.2019.152310_bib0240","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1476-7120-10-40","article-title":"Early detection of doxorubicin myocardial injury by ultrasonic tissue characterization in an experimental animal model","volume":"10","author":"Romano","year":"2012","journal-title":"Cardiovasc. Ultrasound"},{"key":"10.1016\/j.tox.2019.152310_bib0245","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2147\/NDT.S4716","article-title":"Pregabalin for the management of partial epilepsy","volume":"4","author":"Ryvlin","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"87","key":"10.1016\/j.tox.2019.152310_bib0250","first-page":"838","article-title":"Pregabalin-induced first degree atrioventricular block in a young patient treated for pain from extrapulmonary tuberculosis","author":"Schiavo","year":"2017","journal-title":"Monaldi Arch. Chest Dis."},{"key":"10.1016\/j.tox.2019.152310_bib0255","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jphs.2017.06.003","article-title":"Pregabalin reduces cisplatin-induced mechanical allodynia in rats","volume":"134","author":"Seto","year":"2017","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.tox.2019.152310_bib0260","first-page":"1149","article-title":"Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats","volume":"16","author":"Sharp","year":"2015","journal-title":"J. Renin. Syst."},{"key":"10.1016\/j.tox.2019.152310_bib0265","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12906-017-1577-7","article-title":"Ameliorative potential of Alstonia scholaris (Linn.) R. Br. against chronic constriction injury-induced neuropathic pain in rats","volume":"17","author":"Singh","year":"2017","journal-title":"BMC Complement. Altern. Med."},{"key":"10.1016\/j.tox.2019.152310_bib0270","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1540-8175.2001.00029.x","article-title":"Echocardiography-the gold standard of the new millennium: replacing the historical gold standard of cardiac catheterization","volume":"18","author":"Sorrell","year":"2001","journal-title":"Echocardiography."},{"key":"10.1016\/j.tox.2019.152310_bib0275","first-page":"319","article-title":"Different cross-talk sites between the renin\u2013angiotensin and the kallikrein\u2013kinin systems","volume":"15","author":"Su","year":"2014","journal-title":"J. Renin. Syst."},{"key":"10.1016\/j.tox.2019.152310_bib0280","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.2174\/1381612823666170622112253","article-title":"Role of bradykinin in the regulation of endothelial nitric oxide synthase expression by cardiovascular drugs","volume":"23","author":"Su","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.tox.2019.152310_bib0285","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.7150\/ijbs.7.1077","article-title":"Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2\/angiotensin 1-7\/mas receptor axis","volume":"7","author":"Sukumaran","year":"2011","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.tox.2019.152310_bib0290","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/hr.2010.67","article-title":"Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy","volume":"33","author":"Sukumaran","year":"2010","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.tox.2019.152310_bib0295","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12872-017-0686-z","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials","volume":"17","author":"Tai","year":"2017","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.tox.2019.152310_bib0300","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1253\/circj.CJ-08-1071","article-title":"Peroxisome proliferator-activated receptor \u03b3 and cardiovascular diseases","volume":"73","author":"Takano","year":"2009","journal-title":"Circ. J."},{"key":"10.1016\/j.tox.2019.152310_bib0305","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinthera.2007.01.013","article-title":"Pregabalin: a novel \u03b3-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders","volume":"29","author":"Tassone","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.tox.2019.152310_bib0310","first-page":"S7","article-title":"The role of the rennin-angiotensin-aldosterone system in heart failure","volume":"5","author":"Unger","year":"2004","journal-title":"J. Renin. Syst."},{"key":"10.1016\/j.tox.2019.152310_bib0315","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2005.11.001","article-title":"Activity profile of pregabalin in rodent models of epilepsy and ataxia","volume":"68","author":"Vartanian","year":"2006","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.tox.2019.152310_bib0320","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/1570159X1201140117162802","article-title":"Pregabalin in neuropathic pain: evidences and possible mechanisms","volume":"12","author":"Verma","year":"2014","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.tox.2019.152310_bib0325","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1753944708091777","article-title":"The therapeutic role of RAS blockade in chronic heart failure","volume":"2","author":"Werner","year":"2008","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"10.1016\/j.tox.2019.152310_bib0330","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1042\/CS20120341","article-title":"Protective role of AT2 and B1 receptors in kinin B2-receptor-knockout mice with myocardial infarction","volume":"124","author":"Xu","year":"2013","journal-title":"Clin. Sci."},{"key":"10.1016\/j.tox.2019.152310_bib0335","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1248\/bpb.31.2045","article-title":"Ameliorative effect of captopril and valsartan on an animal model of diabetic cardiomyopathy","volume":"31","author":"Zhang","year":"2008","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.tox.2019.152310_bib0340","doi-asserted-by":"crossref","first-page":"108780","DOI":"10.1016\/j.biopha.2019.108780","article-title":"Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a\/\u03b2-catenin and Jak2\/Stat3 pathways","volume":"113","author":"Zhang","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tox.2019.152310_bib0345","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.regpep.2010.09.005","article-title":"Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression","volume":"166","author":"Zhong","year":"2011","journal-title":"Regul. Pept."},{"key":"10.1016\/j.tox.2019.152310_bib0350","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0735-1097(99)00592-6","article-title":"Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion","volume":"35","author":"Zhu","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.tox.2019.152310_bib0355","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/aps.2011.96","article-title":"Regulation of angiotensin-(1\u20137) and angiotensin II type 1 receptor by telmisartan and losartan in adriamycin-induced rat heart failure","volume":"32","author":"Zong","year":"2011","journal-title":"Acta Pharmacol. Sin."}],"container-title":["Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X19302677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X19302677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T23:42:10Z","timestamp":1759534930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300483X19302677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":71,"alternative-id":["S0300483X19302677"],"URL":"https:\/\/doi.org\/10.1016\/j.tox.2019.152310","relation":{},"ISSN":["0300-483X"],"issn-type":[{"value":"0300-483X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Telmisartan and captopril ameliorate pregabalin-induced heart failure in rats","name":"articletitle","label":"Article Title"},{"value":"Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tox.2019.152310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152310"}}